SEC Form 4 · accession 0001209191-19-010148

Deciphera Pharmaceuticals, Inc. · DCPH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and CEO · Director

Period of report

Feb 12, 2019

Accepted (ET)

Feb 14, 2019 · 4:23 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001654151

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Feb 12, 2019	M	200	$1.89	A	200	D
Common Stock	Feb 12, 2019	S	200	$28.00	D	0	D
Common Stock	Feb 13, 2019	M	2,666	$1.89	A	2,666	D
Common Stock^F2	Feb 13, 2019	S	2,666	$28.0034	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F3	$1.89	Feb 12, 2019	M	200	D	—	Dec 17, 2025	Common Stock	200	551,732	D
Stock Option (Right to Buy)^F3	$1.89	Feb 13, 2019	M	2,666	D	—	Dec 17, 2025	Common Stock	2,666	549,066	D

F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.02, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal quarterly installments at the end of each quarter following the vesting commencement date of March 1, 2014, subject to continued service through such dates.